Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and ECG Data on Brolucizumab in nAMD
NCT03954626Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Primary endpoint: Frequency of Clinically Relevant Treatment Emergent ECG Changes. Started Jun 2019; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03954626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954626.